GlassScriptPhysician profile
Nadira Ahmed
NPI 1295806784
$3,933.75
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $1,074 · 2021: $1,192 · 2022: $796.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $765.17 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $587.39 | 2019-2022 | |
| Novo Nordisk INC | $496.08 | 2019-2022 | |
| Lilly USA, LLC | $334.71 | 2019-2022 | |
| Allergan, INC. | $235.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $143.31 | 2019-2022 | |
| Esperion Therapeutics, INC. | $140.56 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $135.40 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $124.37 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $89.29 | 2019-2020 | |
| Abbvie INC. | $87.63 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $78.86 | 2019-2022 | |
| Abbott Laboratories | $64.13 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $60.97 | 2021-2022 | |
| Pfizer INC. | $49.82 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.49 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $48.41 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.22 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $19.26 | 2022 | |
| Novum Pharma, LLC | $13.85 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.23 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadira Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.